Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance

Now Viewing

EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.

Mardones discusses toxicities associated with oral selective estrogen receptor degraders (SERDs) with Vidal, Callahan, and Gradishar. Vidal addresses cardiovascular, reproductive, and bone health, noting potential toxicities in some oral SERDs but emphasizing their overall well-tolerated nature and how they provide clinicians with effective alternatives to chemotherapy. Callahan delves into nausea and gastrointestinal toxicities, citing a learning curve and advising patients to take the drug with food to minimize adverse effects. The patient-reported outcomes data presented at the 2023 European Society for Medical Oncology Congress suggests an improvement in patient-reported nausea and vomiting, enhancing the overall experience. Gradishar emphasizes that oral SERDs, particularly elacestrant, maintain quality of life with minimal adverse effects and improved tolerability compared with chemotherapy. Vidal highlights the evolving landscape of prior authorization, acknowledging initial challenges but noting improved processes, voucher programs, and timely access to drugs, which streamlines the patient experience. This discussion offers a comprehensive view of the toxicities associated with oral SERDs and insights into managing patient experiences in clinical practice.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.